DelveInsight’s “Castrate-resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Castrate-resistant Prostate Cancer, historical and forecasted epidemiology as well as the Castrate-resistant Prostate Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Castrate-resistant Prostate Cancer, offering comprehensive insights into the Castrate-resistant Prostate Cancer revenue trends, prevalence, and treatment landscape. The report delves into key Castrate-resistant Prostate Cancer statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Castrate-resistant Prostate Cancer therapies. Additionally, we cover the landscape of Castrate-resistant Prostate Cancer clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Castrate-resistant Prostate Cancer treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Castrate-resistant Prostate Cancer space.
To Know in detail about the Castrate-resistant Prostate Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Castrate-resistant Prostate Cancer Market Forecast
Some of the key facts of the Castrate-resistant Prostate Cancer Market Report:
The Castrate-resistant Prostate Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In September 2024, Ipsen reported that the Phase III CONTACT-02 trial evaluating Cabometyx and atezolizumab for metastatic castration-resistant prostate cancer (mCRPC) demonstrated a non-significant improvement in overall survival but successfully met the progression-free survival (PFS) endpoint.
In August 2024, Nuvation Bio announced that the U.S. Food and Drug Administration has approved its investigational new drug application to assess NUV-1511, the first clinical candidate from the company’s innovative drug-drug conjugate (DDC) platform.
In July 2024, The FDA has awarded fast-track designation to SYNC-T SV-102 for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Key Castrate-resistant Prostate Cancer Companies: Janssen Research & Development, Pfizer, Astellas Pharma, Bristol-Myers Squibb, Laekna Therapeutics, Novartis, Hinova, AstraZeneca, Effector Therapeutics, Hinova pharmaceuticals, POINT Biopharma, Exelixis, Tavanta Therapeutics, Pfizer, Zenith Epigenetics, Surface Oncology, Opna-IO LLC, Taiho oncology, Arvinas, Forma therapeutics, ESSA Pharma, Oncternal, Janux Therapeutics, and others.
Key Castrate-resistant Prostate Cancer Therapies: Niraparib, Talzenna, Opdivo (nivolumab), LAE001, 177Lu-PSMA617, HC-1119, AZD4635, tomivosertib (eFT508), Enzalutamide, and others
The Castrate-resistant Prostate Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Castrate-resistant Prostate Cancer pipeline products will significantly revolutionize the Castrate-resistant Prostate Cancer market dynamics.
Prostate cancer is the third most prevalent type of cancer in the US and the fourth most common worldwide. Approximately 1 in 9 men in the US will be diagnosed with prostate cancer at some point in their lives
The total diagnosed cases of CRPC in the 7MM were found to be 2,692,615 in 2021 which is expected to grow during the study period
The total prevalent cases of prostate cancer in the 7MM were observed to be 7,726,394 cases in 2021 which is expected to grow during the study period (2019–2032). In total prevalent cases of the 7MM; the US accounted for highest number of cases which were 3,581,872 cases in 2021
Among the EU-5 countries, Germany had the highest diagnosed prevalence of Prostate Cancer, followed by France and Italy. On the other hand, Spain had the lowest diagnosed prevalent population in2021. Furthermore, in total diagnosed cases of the7MM; Japan accounted for 252,141cases of in 2021
Castrate-resistant Prostate Cancer Overview
Castrate-resistant prostate cancer (CRPC) is a type of prostate cancer that continues to grow and progress despite low levels of testosterone, typically achieved through androgen deprivation therapy (ADT). Initially, prostate cancer is often responsive to treatments that reduce testosterone, but over time, some cancer cells adapt and become resistant to these therapies. CRPC can manifest with rising prostate-specific antigen (PSA) levels, new symptoms, or metastasis. It is associated with a more aggressive disease course and requires alternative treatment strategies, such as chemotherapy, novel hormonal therapies, or targeted therapies, to manage the condition.
Get a Free sample for the Castrate-resistant Prostate Cancer Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/castrate-resistant-prostate-cancer-market
Castrate-resistant Prostate Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Castrate-resistant Prostate Cancer Epidemiology Segmentation:
The Castrate-resistant Prostate Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalence of Castrate-resistant Prostate Cancer
Prevalent Cases of Castrate-resistant Prostate Cancer by severity
Gender-specific Prevalence of Castrate-resistant Prostate Cancer
Diagnosed Cases of Episodic and Chronic Castrate-resistant Prostate Cancer
Download the report to understand which factors are driving Castrate-resistant Prostate Cancer epidemiology trends @ Castrate-resistant Prostate Cancer Epidemiology Forecast
Castrate-resistant Prostate Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Castrate-resistant Prostate Cancer market or expected to get launched during the study period. The analysis covers Castrate-resistant Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Castrate-resistant Prostate Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Castrate-resistant Prostate Cancer Therapies and Key Companies
Niraparib: Janssen Research & Development
Talzenna: Pfizer/Astellas Pharma
Opdivo (nivolumab): Bristol-Myers Squibb
LAE001: Laekna Therapeutics
177Lu-PSMA617: Novartis
HC-1119: Hinova
Discover more about therapies set to grab major Castrate-resistant Prostate Cancer market share @ Castrate-resistant Prostate Cancer Treatment Landscape
Castrate-resistant Prostate Cancer Market Drivers
Rising Geriatric Population and High Prevalence Rate of Castrate-resistant Prostate Cancer
Increase in Demand for Castrate-resistant Prostate Cancer Treatment
Products Surge in Awareness Regarding the Treatment of Castrate-resistant Prostate Cancer
Innovation in drugs and developments in genomics and proteomics
Castrate-resistant Prostate Cancer Market Barriers
Cost Constraints
The Complex issue of Companion Diagnostics
Entry Barrier
Diagnostic challenges
Scope of the Castrate-resistant Prostate Cancer Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Castrate-resistant Prostate Cancer Companies: Janssen Research & Development, Pfizer, Astellas Pharma, Bristol-Myers Squibb, Laekna Therapeutics, Novartis, Hinova, AstraZeneca, Effector Therapeutics, Hinova pharmaceuticals, POINT Biopharma, Exelixis, Tavanta Therapeutics, Pfizer, Zenith Epigenetics, Surface Oncology, Opna-IO LLC, Taiho oncology, Arvinas, Forma therapeutics, ESSA Pharma, Oncternal, Janux Therapeutics, and others
Castrate-resistant Prostate Cancer Therapeutic Assessment: Castrate-resistant Prostate Cancer current marketed and Castrate-resistant Prostate Cancer emerging therapies
Castrate-resistant Prostate Cancer Market Dynamics: Castrate-resistant Prostate Cancer market drivers and Castrate-resistant Prostate Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Castrate-resistant Prostate Cancer Unmet Needs, KOL’s views, Analyst’s views, Castrate-resistant Prostate Cancer Market Access and Reimbursement
To know more about Castrate-resistant Prostate Cancer companies working in the treatment market, visit @ Castrate-resistant Prostate Cancer Clinical Trials and Therapeutic Assessment
Table of Contents
1. Castrate-resistant Prostate Cancer Market Report Introduction
2. Executive Summary for Castrate-resistant Prostate Cancer
3. SWOT analysis of Castrate-resistant Prostate Cancer
4. Castrate-resistant Prostate Cancer Patient Share (%) Overview at a Glance
5. Castrate-resistant Prostate Cancer Market Overview at a Glance
6. Castrate-resistant Prostate Cancer Disease Background and Overview
7. Castrate-resistant Prostate Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Castrate-resistant Prostate Cancer
9. Castrate-resistant Prostate Cancer Current Treatment and Medical Practices
10. Castrate-resistant Prostate Cancer Unmet Needs
11. Castrate-resistant Prostate Cancer Emerging Therapies
12. Castrate-resistant Prostate Cancer Market Outlook
13. Country-Wise Castrate-resistant Prostate Cancer Market Analysis (2019–2032)
14. Castrate-resistant Prostate Cancer Market Access and Reimbursement of Therapies
15. Castrate-resistant Prostate Cancer Market Drivers
16. Castrate-resistant Prostate Cancer Market Barriers
17. Castrate-resistant Prostate Cancer Appendix
18. Castrate-resistant Prostate Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
